Four pregnancies following adolescent treatment for rare undifferentiated vulvar sarcoma, achieved after administering 17.6 g/m² of cyclophosphamide and 45 Gy of pelvic radiation, demonstrate that successful reproduction remains possible after high-exposure pediatric oncology therapies, Cureus reported.
In Plain English: The Clinical Takeaway
- Cyclophosphamide Exposure: The patient received a cumulative dose of 17.6 g/m² of cyclophosphamide, a chemotherapy medication that damages DNA to stop cancer cells from multiplying but carries a significant risk of causing infertility.
- Pelvic Radiation Dosimetry: Targeted radiation delivered a total dose of 45 Gy in 25 fractions to the left pelvic cavity, with an estimated uterine radiation exposure of approximately 15 Gy.
- Obstetric Management: Subsequent pregnancies required intensive monitoring and interventions, including elective prophylactic cervical cerclage and uterine artery embolization for retained placental tissue, to manage complications linked to prior pelvic irradiation.
Adolescent Sarcoma Diagnosis and Initial Treatment
When she was 15 years old, the patient first sought medical attention for a one-month history of induration, erythema, and swelling in the left vulva, as documented by Cureus. Following evaluation at a local clinic, she was referred because of a progressively enlarging vulvar mass measuring approximately 8 cm.
Tumor excision and a left inguinal lymph node biopsy established the diagnosis of INI-1-negative undifferentiated vulvar sarcoma. Postoperative positron emission tomography revealed metastasis confined to the left inguinal lymph nodes.
This finding necessitated left inguinal lymphadenectomy followed by pelvic radiation therapy. Using 10-MV X-rays generated by a linear accelerator, photon radiotherapy was administered through opposing anterior-posterior fields that covered the left vulvar tumor bed and inguinal lymph node area.
The total dosage prescribed reached 45 Gy split across 25 fractions, with the uterus estimated to have received roughly 15 Gy of exposure. Chemotherapy consisted of nine cycles of vincristine, actinomycin D, and cyclophosphamide, followed by one cycle of irinotecan plus vincristine.
The total cumulative dose of cyclophosphamide reached 17.6 g/m², and the entire treatment course was completed within approximately one year. Subsequently, she developed radiation-induced cystitis, which required hyperbaric oxygen therapy for two months starting at the age of 16 years.
Four Pregnancies After Oncologic Therapy
Her menstrual cycle stayed regular until she turned 19, at which point cycle irregularities led to a single round of Kaufmann therapy in order to normalize her periods. Spontaneous menstruation continued until her first pregnancy at the age of 25 years, Cureus reported.
During her first pregnancy at age 25, she was hospitalized at 30 weeks and six days of gestation because of a short cervix. At 36 weeks and four days, she vaginally delivered a male infant weighing 2,522 g, and the delivery was complicated by postpartum hemorrhage due to uterine atony.
The second pregnancy, which took place when she was 27 years old, concluded in a first-trimester miscarriage at 10 weeks of gestation that was treated via dilation and evacuation at another medical facility. The third pregnancy, also at age 27, presented at 17 weeks and five days of gestation with cervical dilation and prolapsed fetal membranes, Cureus reported.
Despite conservative management including strict bed rest and intravenous ritodrine hydrochloride for tocolysis, the pregnancy ended in a miscarriage at 19 weeks and two days. This third pregnancy was complicated by chorioamnionitis and suspected placenta accreta due to retained placental tissue.
At 32 days postpartum following the third pregnancy, heavy vaginal bleeding prompted an MRI that revealed retained placental tissue and a pseudoaneurysm. Following uterine artery embolization, the remaining placental tissue spontaneously passed at 43 days postpartum.
The fourth pregnancy was conceived naturally and presented at 10 weeks and three days of gestation. Transvaginal ultrasonography showed a cervical length of 27 mm, and elective prophylactic cervical cerclage using the Shirodkar procedure was performed at 12 weeks and five days of gestation.
An MRI of the pelvis performed at 35 weeks and 4 days indicated no signs pointing toward placenta accreta, allowing for the removal of the cerclage suture at 36 weeks and 2 days. Labor was induced at 37 weeks and two days, resulting in the vacuum-assisted delivery of a male infant weighing 2,366 g with Apgar scores of 8 and 9.
| Pregnancy Number | Maternal Age | Gestational Age at Delivery/Loss | Key Obstetric Outcome |
|---|---|---|---|
| First Pregnancy | 25 years | 36 weeks, 4 days | Vaginal delivery of male infant (2,522 g); complicated by postpartum hemorrhage. |
| Second Pregnancy | 27 years | 10 weeks | First-trimester miscarriage managed by dilation and evacuation. |
| Third Pregnancy | 27 years | 19 weeks, 2 days | Miscarriage complicated by chorioamnionitis, placenta accreta, and pseudoaneurysm. |
| Fourth Pregnancy | 30 years | 37 weeks, 2 days | Induction of labor following prophylactic cervical cerclage; live male infant (2,366 g). |
Evaluating Chemotherapy and Pelvic Radiation Doses
Alkylating agents, particularly cyclophosphamide, are associated with diminished ovarian reserve and infertility in cancer survivors. The patient’s cumulative dose of 17.6 g/m² corresponds to a cyclophosphamide equivalent dose (CED) of 17,600 mg/m², Cureus reported.
In a European case-control study involving 1,332 female childhood, adolescent, and young adult cancer survivors, a CED exceeding 7,121 mg/m² was associated with an increased risk of fertility impairment. The CED stratum encompassing this patient’s exposure carried an odds ratio of 2.7 for fertility impairment.
Pelvic irradiation at doses exceeding 5-10 Gy risks uterine volume, vascularization, and elasticity, potentially affecting pregnancy outcomes. A French cohort study of 1,159 female childhood cancer survivors demonstrated an association between higher uterine radiation doses and adverse pregnancy outcomes.
Among pregnancies in women with a median uterine radiation dose exceeding 20 Gy, the combined proportion of adverse pregnancy outcomes was 39%, compared with 12% in the general population. Although the estimated uterine dose in this patient was approximately 15 Gy, specific dosimetric parameters within the uterus could not be retrospectively verified.
Risks and Required Medical Consultation for Survivors
Patients with a history of cumulative alkylating chemotherapy doses or pelvic radiation exceeding 5-10 Gy face elevated risks of uterine factor infertility, cervical insufficiency, and severe obstetric complications such as placenta accreta and postpartum hemorrhage.
Individuals with a prior history of childhood or adolescent cancer who experience menstrual irregularities, secondary amenorrhea, or who are planning pregnancy should immediately consult a multidisciplinary care team involving maternal-fetal medicine specialists and oncologists for comprehensive risk stratification, preconception counseling, and early gestational surveillance.
Annual oncologic surveillance confirmed no evidence of disease recurrence throughout the patient’s reproductive years. Both surviving children have demonstrated normal growth and development, Cureus reported.
References
- Cureus: Four Pregnancies Following Chemotherapy and Pelvic Radiotherapy During Adolescence for Undifferentiated Vulvar Sarcoma: A Case Report
- European Journal of Cancer: Cyclophosphamide Equivalent Dose and Fertility Impairment in Female Childhood Cancer Survivors
- Radiation Research: Uterine Radiation Doses and Pregnancy Outcomes in Childhood Cancer Survivors
